GLP-1 & compounded medication availability in Minnesota (2026)
Minnesota’s pharmacy regulator put GLP-1 medications on the front page of its January 2026 newsletter, not to restrict them, but to warn about sloppy titration prescribing, unlicensed suppliers behind med-spa counters, and compounded product moving outside proper channels. That bulletin is quoted below, verbatim and linked, because it is the best available statement of what Minnesota is watching for, and because everything it warns against is what ordering through licensed, patient-specific channels avoids.
Minnesota availability across all ten lines
| Product line | Available in Minnesota? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Dispensed with a patient-specific label, the exact practice Minnesota’s regulator says to insist on. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Flat national pricing; dose changes never change the bill. |
| NAD+ | Yes | 8–10 business days | From pharmacies licensed by Minnesota for out-of-state dispensing. |
| Sermorelin | Yes | 8–10 business days | Standard eligibility flow, standard national price. |
| Glutathione | No | N/A | Not offered by OrderlyMeds at present. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; its federal entry below is specific to it. |
| TB-500 | Yes | 8–10 business days | Compounded injectable. Cited federal record directly below. |
| KPV | No | N/A | Absent from the formulary in every state; peptides here are injectable-only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; the federal facts below are load-bearing. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; federally it is the odd one out, as its section explains. |
Rows never vanish to flatter the catalog. Unavailable means a printed No. Minnesota data reviewed November 16, 2026.
Research peptides in Minnesota: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Minnesota addresses can receive four of these five peptide lines from OrderlyMeds: BPC-157, TB-500, Epitalon and MOTS-c, each one a compounded injectable dispensed against a prescription naming you, with the patient-specific label Minnesota’s regulator tells patients to look for. KPV is not among them; our peptide compounding is injectable-only and KPV is not compounded that way. Five substances, five distinct federal records, each stated below without varnish.
BPC-157 in Minnesota
Ships to Minnesota as a compounded injectable with a patient-specific label and prescription. Its federal standing:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Minnesota
Available for Minnesota patients as an individually prescribed compounded injectable. On the federal side:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Minnesota
Not dispensed to Minnesota, or anywhere. KPV falls outside the injectable-only peptide formulary.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Minnesota
An individually prescribed compounded injectable for Minnesota addresses. Federal record as follows:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Minnesota
Delivered to Minnesota as a compounded injectable on an individual prescription; read its federal entry on its own terms:
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Minnesota’s pharmacy regulator is saying right now
Minnesota pairs a strict licensing baseline with an unusually vocal regulator. The licensing side is old and settled: out-of-state pharmacies need Minnesota licenses, site by site. The vocal side is new and specific: a January 2026 bulletin that reads like a field report on exactly the corners of the GLP-1 market a careful patient should avoid. Both are cited here; the bulletin deserves quoting at length.
Every pharmacy dispensing to Minnesota residents — including one located outside the state — must be licensed by Minnesota, with a separate license for each location where any portion of the dispensing occurs, and must agree to follow Minnesota law when dispensing to the state’s residents. Minn. Stat. § 151.19, subd. 1. Source: Minnesota Statutes § 151.19.
In its January 2026 newsletter, Minnesota’s Board of Pharmacy reported “multiple reports regarding the potentially inappropriate use or distribution” of GLP-1 injectables (semaglutide and tirzepatide), said compounded GLP-1s and unapproved compounded combinations “continue to be provided despite Food and Drug Administration (FDA) guidance,” described ongoing awareness of unlicensed pharmacies supplying med-spa and lifestyle clinics, and stated that any medication received through such a clinic is required to have a patient-specific label with all the same information expected on a pharmacy label. Source: Minnesota Board of Pharmacy newsletter, January 2026 (Vol. 47, No. 1).
A physician-patient relationship may be established through telehealth in Minnesota, and care delivered by telehealth is held to the same standards of practice and conduct as in-person care. Minn. Stat. § 147.033. Source: Minnesota Statutes § 147.033.
Read the bulletin’s warnings as a checklist and OrderlyMeds checks out item by item: licensed pharmacies rather than mystery suppliers, one prescription and one concentration per patient rather than a stack of titration scripts, and a patient-specific label on the package, the very thing the regulator tells Minnesotans to demand. The price is the national one on our pricing page; Minneapolis, Rochester and Bemidji pay the same.
Minnesota availability FAQs
Is compounded semaglutide available to Minnesota residents?
Yes, dispensed by pharmacies holding Minnesota licenses, with the patient-specific label the state’s regulator says every such medication must carry. New customers start at $74/month for the first two months.
What did Minnesota’s regulator say about GLP-1s in 2026?
Its January 2026 newsletter flagged inappropriate-use reports, dispensing errors from multi-dose titration prescribing, and unlicensed pharmacies behind med-spa counters, quoted verbatim and linked above.
Which peptide lines ship to Minnesota?
Four: BPC-157, TB-500, Epitalon and MOTS-c, each a compounded injectable on an individual prescription. KPV is not carried in any state. Their separate federal records are stated on this page.
What is the delivery estimate for Minnesota?
The published OrderlyMeds window is 8–10 business days from signup, and Minnesota orders follow it.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
